AI-generated summary
The authors report a double-blind randomized controlled trial of a 980 nm GaAs laser added to standard medication for myofascial pain dysfunction and other orofacial pain. Both the laser group and the sham control group showed significant pain reduction over time, but the difference between groups was not significant, so the authors found no significant efficacy for the laser.
- Who or what was studied
- Patients with orofacial pain, including myofascial pain dysfunction syndrome, randomized into laser (n=30) and sham control (n=30) groups
- Wavelengths
- 980 nm
- Limits stated in the abstract
- The abstract notes that the study had no significant result against control and suggests covariates such as wavelength and dose may matter, leaving the findings inconclusive.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 980 nm
- Power
- 10 W, 0.012 W
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Randomized controlled trial, Control group, Dose, Visual analogue scale, Wavelength, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.